In European legal contexts, refers to a specific decision by the European Patent Office (EPO) Boards of Appeal regarding ZTE Corporation.
It is specifically indicated for the treatment of pediatric patients with high-risk neuroblastoma . 125516
It is typically administered in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-2 (IL-2), and 13-cis-retinoic acid (RA). In European legal contexts, refers to a specific
On developer platforms like Stack Overflow , users with ID 125516 or similar numerical identifiers contribute to technical discussions regarding software like Visual Studio Code. T 1255/16 (Irregular LDPC code/ZTE) of 15.02.2019 In European legal contexts